Shopping Cart
Remove All
Your shopping cart is currently empty
Sudubrilimab
(Synonyms: HS636) Copy Product Info
🥰Excellent
Synonyms: HS636
Catalog No. T77189 Copy Product Info
🥰Excellent
Sudubrilimab is an innovative bifunctional fusion protein designed to simultaneously target two key inhibitory pathways in the tumor microenvironment: the PD-1/PD-L1 immune checkpoint and the TGF-beta signaling axis. The compound consists of a humanized anti-PD-L1 monoclonal antibody fused to the extracellular domain of TGF-beta receptor II (TGFBR2-ECD). Serving as an essential tool for investigating the reversal of tumor immunosuppression and the enhancement of effector cell function, its design aims to overcome resistance to single-target therapies through synergistic action.
Cas No. 2387417-06-1
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $290 | - | In Stock | |
| 5 mg | $871 | - | In Stock | |
| 10 mg | $1,390 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:96.1% (SDS-PAGE); 98.4% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Sudubrilimab is an innovative bifunctional fusion protein designed to simultaneously target two key inhibitory pathways in the tumor microenvironment: the PD-1/PD-L1 immune checkpoint and the TGF-beta signaling axis. The compound consists of a humanized anti-PD-L1 monoclonal antibody fused to the extracellular domain of TGF-beta receptor II (TGFBR2-ECD). Serving as an essential tool for investigating the reversal of tumor immunosuppression and the enhancement of effector cell function, its design aims to overcome resistance to single-target therapies through synergistic action. |
| In vitro | In PD-L1 and TGF-beta binding assays, Sudubrilimab bound specifically to both targets and enhanced IFN-gamma production in T-cell activation assays [1]. |
| Synonyms | HS636 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | B7-H1/PD-L1/CD274 |
| Cas No. | 2387417-06-1 |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | Store at low temperature Store at -20°C Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: Sudubrilimab chemical structure | Sudubrilimab in vitro
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.